WINTON GROUP Ltd Makes New $2.35 Million Investment in Mineralys Therapeutics, Inc. $MLYS

WINTON GROUP Ltd bought a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 64,806 shares of the company’s stock, valued at approximately $2,352,000. WINTON GROUP Ltd owned 0.08% of Mineralys Therapeutics at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Hudson Bay Capital Management LP purchased a new position in shares of Mineralys Therapeutics during the 3rd quarter worth $2,873,000. SG Americas Securities LLC boosted its stake in shares of Mineralys Therapeutics by 130.7% during the 4th quarter. SG Americas Securities LLC now owns 230,795 shares of the company’s stock worth $8,376,000 after acquiring an additional 130,758 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Mineralys Therapeutics by 29.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after acquiring an additional 692,550 shares during the last quarter. Citigroup Inc. boosted its stake in shares of Mineralys Therapeutics by 501.7% during the 3rd quarter. Citigroup Inc. now owns 163,168 shares of the company’s stock worth $6,187,000 after acquiring an additional 136,050 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Mineralys Therapeutics by 234.4% during the 4th quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock worth $45,677,000 after acquiring an additional 882,307 shares during the last quarter. Institutional investors own 84.46% of the company’s stock.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,730 shares of Mineralys Therapeutics stock in a transaction on Monday, April 13th. The shares were sold at an average price of $26.83, for a total value of $422,035.90. Following the sale, the chief executive officer directly owned 689,321 shares in the company, valued at approximately $18,494,482.43. The trade was a 2.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ra Capital Management, L.P. purchased 310,700 shares of Mineralys Therapeutics stock in a transaction on Friday, March 27th. The stock was bought at an average price of $23.67 per share, for a total transaction of $7,354,269.00. Following the completion of the acquisition, the director owned 5,767,221 shares in the company, valued at $136,510,121.07. The trade was a 5.69% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have sold 160,120 shares of company stock valued at $4,295,413. 18.94% of the stock is currently owned by insiders.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ MLYS opened at $23.69 on Monday. The company has a market cap of $1.95 billion, a P/E ratio of -11.56 and a beta of 0.57. The firm’s fifty day moving average is $27.95 and its two-hundred day moving average is $31.18. Mineralys Therapeutics, Inc. has a 52-week low of $12.59 and a 52-week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They set a “buy” rating on the stock. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Finally, Bank of America lifted their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.33.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.